EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Open Access · CC BY-NC-ND 4.0

A Randomized, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of VIR-2482 in Healthy Adults for Prevention of Influenza A Illness (PENINSULA)

Susanna K Tan iD, Deborah Cebrik, David Plotnik, Maria L Agostini, Keith Boundy, Christy M Hebner, Wendy W Yeh, Phillip S Pang, Jaynier Moya, Charles Fogarty, Manuchehr Darani, Frederick G Hayden

Clinical Infectious Diseases · 2024

DOI: 10.1093/cid/ciae368 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, 2024. Verfasst von Susanna K Tan und 11 weiteren Autor:innen. Beteiligte Einrichtung: Vir Biotechnology, Inc., San Francisco, California, USA. Hauptthemen laut MEDLINE: Influenza, Human. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Vir Biotechnology, Inc, HHS, Administration for Strategic Preparedness and Response.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Influenza A results in significant morbidity and mortality. VIR-2482, an engineered human monoclonal antibody with extended half-life, targets a highly conserved epitope on the stem region of influenza A hemagglutinin and may protect against seasonal and pandemic influenza.

Methods

This double-blind, randomized, placebo-controlled, phase 2 study examined the safety and efficacy of VIR-2482 for seasonal influenza A illness prevention in unvaccinated healthy adults.

Participants

(N = 2977) were randomized 1:1:1 to receive VIR-2482 450 mg, VIR-2482 1200 mg, or placebo via intramuscular injection. Primary and secondary efficacy endpoints were the proportions of participants with reverse transcriptase-polymerase chain reaction–confirmed influenza A infection and either protocol-defined influenza-like illness (ILI) and Centers for Disease Control and Prevention–defined ILI or World Health Organization–defined ILI, respectively.

Results

VIR-2482 450 mg and 1200 mg prophylaxis did not reduce the risk of protocol-defined ILI with reverse transcriptase-polymerase chain reaction–confirmed influenza A versus placebo (relative risk reduction, 3.8% [95% confidence interval (CI), −67.3 to 44.6] and 15.9% [95% CI, −49.3 to 52.3], respectively). At the 1200-mg dose, the relative risk reductions in influenza A illness were 57.2% (95% CI: −2.5 to 82.2) using Centers for Disease Control and Prevention ILI and 44.1% (95% CI: −50.5 to 79.3) using World Health Organization ILI definitions, respectively. Serum VIR-2482 levels were similar regardless of influenza status; variants with reduced VIR-2482 susceptibility were not detected. Local injection site reactions were mild and similar across groups.

Conclusions

VIR-2482 1200 mg intramuscular was well tolerated but did not significantly prevent protocol-defined ILI. Secondary endpoint analyses suggest this dose may have reduced influenza A illness.

Trial registration

ClinicalTrials.gov identifier, NCT05567783.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Influenza, HumanHumansAdultMaleFemaleDouble-Blind MethodMiddle AgedYoung AdultAdolescentInfluenza A virusAntibodies, MonoclonalInjections, IntramuscularHealthy VolunteersInfluenza VaccinesAgedAntibodies, Viral

Stichwörter der Autor:innen

VIR-2482influenza Amonoclonal antibodyphase 2 clinical trialseasonal influenza prevention

Substanzen

Antibodies, MonoclonalInfluenza VaccinesAntibodies, Viral

Autor:innen und Institutionen

  • Vir Biotechnology, Inc., San Francisco, California, USA.
  • Pines Care Research Center, Inc., Pembroke Pines, Florida, USA.
  • Spartanburg Medical Research, Spartanburg, South Carolina, USA.
  • Marvel Clinical Research, Long Beach, California, USA.
  • Division of Infectious Diseases and International Health, University of Virginia School of Medicine, Charlottesville, Virginia, USA.

ORCID-Profile: Susanna K Tan

Förderung

  • Vir Biotechnology, Inc
  • HHS
  • Administration for Strategic Preparedness and Response
  • Biomedical Advanced Research and Development Authority

Zitieren

APA

Tan, S. K., Cebrik, D., Plotnik, D., Agostini, M. L., Boundy, K., Hebner, C. M., Yeh, W. W., Pang, P. S., Moya, J., Fogarty, C., Darani, M., & Hayden, F. G. (2024). A Randomized, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of VIR-2482 in Healthy Adults for Prevention of Influenza A Illness (PENINSULA). Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciae368

Vancouver

Tan SK, Cebrik D, Plotnik D, Agostini ML, Boundy K, Hebner CM, et al. A Randomized, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of VIR-2482 in Healthy Adults for Prevention of Influenza A Illness (PENINSULA). Clinical Infectious Diseases. 2024. doi:10.1093/cid/ciae368

BibTeX
@article{Tan2024,
  author = {Tan, Susanna K and Cebrik, Deborah and Plotnik, David and Agostini, Maria L and Boundy, Keith and Hebner, Christy M and Yeh, Wendy W and Pang, Phillip S and Moya, Jaynier and Fogarty, Charles and Darani, Manuchehr and Hayden, Frederick G},
  title = {A Randomized, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of VIR-2482 in Healthy Adults for Prevention of Influenza A Illness (PENINSULA)},
  journal = {Clinical Infectious Diseases},
  year = {2024},
  doi = {10.1093/cid/ciae368}
}
Kostenlos starten →